Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 884578 | ISIN: NO0004822503 | Ticker-Symbol: MKL
Tradegate
25.04.24
09:51 Uhr
11,920 Euro
+0,200
+1,71 %
Branche
IT-Dienstleistungen
Aktienmarkt
Sonstige
1-Jahres-Chart
ATEA ASA Chart 1 Jahr
5-Tage-Chart
ATEA ASA 5-Tage-Chart
RealtimeGeldBriefZeit
11,64011,78018:55
11,66011,76026.04.
ACCESSWIRE
398 Leser
Artikel bewerten:
(2)

iZafe Group, in collaboration with Atea Sweden, has won a procurement potentially worth 42-52 MSEK.

STOCKHOLM, SWEDEN / ACCESSWIRE / October 12, 2023 / iZafe Group (STO:IZAFE-B) iZafe Group AB ("iZafe Group") announces that, in partnership with Atea Sverige AB, they have been awarded a contract with Västra Götalandsregionen for the provision of iZafe's medication dispensers, Dosell. The contract covers 1,800 units, up to a maximum of 2,250 units, with an estimated value of 42-52 MSEK. The agreement is held by Atea Sverige AB.

The contract term is for two years, with the possibility of a further two-year extension, and the contract will be signed no earlier than after a period of 10 days, which is the time that must elapse after awarding, according to procurement regulations, before a contract can be signed.
This is merely a decision of award and is not legally binding until a contract has been entered into.

Contacts

Anders Segerström, Chief Executive Officer
E-mail: anders.segerstrom@izafegroup.com
Phone number: +46 70-875 14 12

iZafe Group AB (publ.)
David Bagares gata 3
111 38 Stockholm

E-mail: ir@izafegroup.com
www.izafegroup.com
eucaps.com/izafe-group

About iZafe Group AB (publ.)

iZafe Group is a Life Science company that conducts research, development and marketing of digital medical solutions and services for safer medication management at home.

The company leads the development of digital drug dispensing through the drug robot Dosell as well as the SaaS solution Pilloxa with the smart pillbox. The company's solutions reduce the risk of incorrect medication in the home, increase compliance, relieve public health care, increase the quality of life for patients and create a safer environment for relatives.

The customers consist of private individuals, pharmaceutical companies and public and private healthcare providers in Sweden, the Nordics and globally. iZafe Group primarily sells through well-established partners who already have long and deep customer relationships with the prioritized customer groups. The head office is in Stockholm.

iZafe Group AB has been listed on the Nasdaq First North Growth Market since 2018. Mangold Fondkommission AB is the company's Certified Adviser. Further information is available at www.izafegroup.com

This information is information that iZafe Group is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-10-12 17:51 CEST.

Image Attachments

Dosell VGR

Attachments

iZafe Group, in collaboration with Atea Sweden, has won a procurement potentially worth 42-52 MSEK.

SOURCE: iZafe Group

View source version on accesswire.com:
https://www.accesswire.com/792399/izafe-group-in-collaboration-with-atea-sweden-has-won-a-procurement-potentially-worth-42-52-msek

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2023 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.